Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.

What problem does this paper attempt to address?

Supplementary Figure 1 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399953.v1

2023-01-01

Abstract:PDF file - 108KB, Supplementary Figure 1 LSECtin is induced to be expressed by murine melanoma tissues.
Supplementary Figure 7 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xing,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xiaoze Du,Tang Li,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399932.v1

2023-01-01

Abstract:PDF file - 78KB, Supplementary Figure 7 Confirmation of LAG-3 expression on T cells.
Supplementary Figure 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xing,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xiaoze Du,Tang Li,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399941

2023-01-01

Abstract:PDF file - 150KB, Supplementary Figure 4 Validation of the specificity of anti-LSECtin.
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399923.v1

2023-01-01

Abstract:<p>PDF file - 71KB, Supplementary Table 1 Characteristics of 7 types of cancer patient in cancer survey array. Supplementary Table 2 Characteristics of patient in melanoma RNA chip. Supplementary Table 3 Characteristics of patient in melanoma IHC chip. Supplementary Table 4. Characteristics of patient in flow cytometry analysis.</p>
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419840

2023-01-01

Abstract:Supplementary figure S4. Immunofluorescence on intratumoral lymphocytes and qRT-PCR assays on TH1-type chemokine expression
Supplementary Figure 4 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392866.v1

2023-01-01

Abstract:PDF file - 1.8MB, MSC-L enhanced inflammation reaction in tumor tissues
Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73<sup>+</sup> Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer

Guoming Hu,Pu Cheng,Jun Pan,Shimin Wang,Qingqing Ding,Jing Zhou,Cheng Liu,Xuan Shao,Liming Huang,Jikun Huang

DOI: https://doi.org/10.1158/2326-6066.22542160.v1

2023-01-01

Abstract:Supplemental Figures 1-12 and Supplementary Tables 1-3
Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401678

2023-01-01

Abstract:PDF file - 570K, LCN2 promotes lung metastasis in balb/c nude mice.
Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Xue Meng,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Li,Xiu‐Ping Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419846.v1

2023-01-01

Abstract:Supplementary figure S2. Gating strategies for flow cytometry analyses.
Supplementary Figure 2 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392872.v1

2023-01-01

Abstract:PDF file - 2MB, MSC, MSC-mock, and MSC-L have similar infiltration pattern in tumor tissues
Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392851.v1

2023-01-01

Abstract:PDF file - 164K
Supplementary Figure 7 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Yanli Pang,Sudheer Kumar Gara,Bhagelu R. Achyut,Zhaoyang Li,Hannah H. Yan,Chi‐Ping Day,Jonathan M. Weiss,Giorgio Trinchieri,John C. Morris,Li Yang

DOI: https://doi.org/10.1158/2159-8290.22530048.v1

2023-01-01

Abstract:Supplementary Figure 7 - PDF file 111K, Characterization of myeloid cells in lung, tumor, spleen, and lymph nodes

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure 1 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure 7 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure 4 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73&lt;sup&gt;+&lt;/sup&gt; Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer

Supplementary Figure 5 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure 2 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 7 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73<sup>+</sup> Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer